Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cognition Therapeutics, Inc

0.4474
+0.03247.81%
Post-market: 0.44740.00000.00%19:58 EDT
Volume:370.67K
Turnover:161.14K
Market Cap:18.59M
PE:-0.47
High:0.4484
Open:0.4300
Low:0.4210
Close:0.4150
Loading ...

Company Profile

Company Name:
Cognition Therapeutics, Inc
Exchange:
NASDAQ
Establishment Date:
2007
Employees:
27
Office Location:
2500 Westchester Ave.,Purchase,New York,United States
Zip Code:
10577
Fax:
- -
Introduction:
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.

Directors

Name
Position
Jack A. Khattar
Director, Chairman of the Board
Lisa Ricciardi
Chief Executive Officer, President and Director
Aaron Fletcher
Director
Brett P. Monia
Director
Mark H. Breedlove
Director
Peggy Wallace
Director

Shareholders

Name
Position
Lisa Ricciardi
Chief Executive Officer, President and Director
James M. O'Brien
Chief Financial Officer